CTLA4 and melanoma: Of note, in recent years a possible synergy between EZH2 inhibition and blocking the inhibitory checkpoint Cytotoxic T-Lymphocyte Associated Protein 4(CTLA-4) has been suggested, preventing melanoma expansion in resistant patients [15,16].